Wockhardt's proprietary antibiotic Zaynich gets mentioned in leading U.K. Medical Journal
A clinically challenging case involving Wockhardt's novel antibiotic Zaynich was recently published in the July 17, 2025 issue of the Journal of Antimicrobial Chemotherapy - AMR, a leading publication by the British Society for Antimicrobial Chemotherapy. The publication details the successful use of Zaynich, a combination of Zidebactam and Cefepime, in treating a critically ill U.S. liver transplant patient suffering from a pan-drug resistant infectionan infection resistant to all available antibiotics in the United States. This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins.
Notably, this patient was infected with two different pathogens - Pseudomonas and Klebsiella, both resistant to all the recently introduced antibiotics such as cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam. The case report detailed the results of genetic analysis of bacterial DNA and determined that Pseudomonas and Klebsiella harbored 4 distinct resistance mechanisms each leading to pan-drug resistance. Initially, the patient was treated for 10 weeks with cefiderocol and eravacycline (a novel tetracycline antibiotic), but the infection persisted, and the Pseudomonas strain became resistant to cefiderocol. The patient continued to suffer from fever and chills, and imaging tests showed new abscesses in the liver clear signs that the infection was not under control.
Given the high risk of transplant failure due to these MDR infections, a multidisciplinary team, including microbiologists, infectious disease experts, oncologists, and transplant surgeons, sought emergency access to Zaynich. The antibiotic was administered for 14 days around the time of the liver transplant. The results were remarkable - within 11 days, the patient improved clinically and transferred from ICU to regular floor, and follow-up imaging showed no signs of active infection. Importantly, the patient remained infection-free even after six weeks of completing treatment with Zaynich, making liver transplant successful and allowing doctors to safely resume chemotherapy for the underlying cancer.
The authors highlighted the role of Zaynich as a potential treatment option for extensively drug resistant infections with extremely limited/no treatment options.
Zaynich is a novel, proprietary antibiotic developed by Wockhardt, combining Zidebactam and Cefepime to combat multi-drug resistant Gram-negative infections. The drug recently completed a global, pivotal Phase III clinical trial, which will support its marketing authorization across international markets. Prior to this, multiple Phase I clinical pharmacology studies involving the Zidebactam/Cefepime combination were successfully conducted in the United States. Zaynich has also completed a multi-indication clinical study in India, specifically targeting carbapenem-resistant infections. To date, more than 50 patients in India and the U.S. suffering from highly resistant infections have been treated with Zaynich under compassionate use programs.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
5 hours ago
- Time of India
"Running Out of Cures": Experts warn of India's silent AMR catastrophe
New Delhi: Antimicrobial resistance (AMR) is no longer a looming global health threat—it is already here, silently claiming thousands of lives across India every week. Infections that were once treatable are now proving deadly, and doctors are increasingly witnessing the failure of even last-resort antibiotics. In a recent ETHealthworld webinar titled 'Running Out of Cures: A Deep Dive into India's Antimicrobial Resistance Crisis,' leading clinicians, researchers, and public health experts dissected the alarming rise of AMR and what India must do—urgently—to contain the fallout. 'When Nothing Works': A Clinician's Dilemma Dr. Tanu Singhal, Infectious Disease Specialist at Mumbai's Kokilaben Dhirubhai Ambani Hospital, recalled devastating cases where no antibiotic proved effective. One such case involved a liver transplant patient battling multiple infections, including a highly drug-resistant Enterococcus faecium. 'The infection was resistant to vancomycin, daptomycin, and linezolid. The only option was tigecycline—unsuitable for bacteremia. We eventually lost her. She left against medical advice, unable to afford prolonged care, and died en route to her home,' she said. Even when effective drugs exist, the cost can be prohibitive. 'We had to import cefiderocol rupees four lakh per day—for an patient with Acinetobacter pneumonia. Though we cured the infection, the patient eventually died of a heart attack due to prolonged hospitalization,' she added. In neonatal care, the scenario is no better. 'Gone are the days when ampicillin and gentamicin were enough. We now see newborns with carbapenem-resistant infections requiring colistin and even imported drugs like cefiderocol,' Dr. Singhal warned, citing India-specific studies showing alarmingly high resistance rates in neonatal sepsis. Hospitals Prepared, But Surveillance Still Fragile While larger hospitals are equipped to manage outbreaks, challenges persist, particularly in smaller and rural facilities. 'Accredited hospitals have adequate manpower and isolation infrastructure for MDR cases,' said Dr. Anita Arora, Director of Medical Operations and IPC Head at Fortis Healthcare. 'But gaps exist in standardization and surveillance, especially across the country's vast non-accredited and tier-2, tier-3 healthcare facilities.' Dr. Raman Gangakhedkar, former ICMR scientist and Distinguished Professor at Symbiosis International University, pointed out the lack of robust, generalizable AMR surveillance data as a major impediment to public health action. 'ICMR's surveillance network includes 20-odd urban tertiary hospitals. That doesn't reflect the national AMR burden. Surveillance must extend to secondary and primary care levels—and even into communities—if we want real change,' he emphasised. India's National Action Plan on AMR, nearing a decade since launch, remains limited in its implementation. 'We have a policy, but not a vertical program like for TB or HIV. That's why AMR doesn't get priority in funding or policy enforcement,' Dr. Gangakhedkar noted. Despite sepsis from multi-drug resistant organisms becoming one of India's top infectious killers, there is no emergency response system. 'We lack a coordinated, multi-stakeholder approach. Without demand from the public or advocacy from clinicians, every death remains anecdotal,' he warned. Dr. Taslimarif Saiyed, Director and CEO of C-CAMP, highlighted the emerging biotech response to AMR through the India AMR Innovation Hub (IAIH). 'Over 80 new diagnostic and therapeutic innovations are in the pipeline, including point-of-care detection tools, small-molecule therapies, peptides, and even mAbs,' he said. Within five years, IAIH aims to bring 15–20 AMR solutions to market. 'Our focus is on affordability, accessibility, and adaptability to Indian healthcare settings. We are also partnering with state governments to test and deploy these solutions,' Dr. Saiyed said. What Fuels the AMR Crisis? Rampant over-the-counter (OTC) use and physician-driven overprescription are key drivers. 'We frequently see patients self-medicating with azithromycin for fever,' said Dr. Singhal. 'There's an urgent need for public campaigns discouraging this behavior and educating people that antibiotics are not for viral infections.' Physician behavior must also change. 'Nearly 70% of outpatient visits are viral, yet antibiotics are often prescribed. Pharmacies dispensing antibiotics without prescriptions must be stopped. The government should crack down on irrational fixed-dose combinations and improve antibiotic quality,' she added. India's AMR crisis is tightly linked to its infectious disease burden. 'If we reduce infections, we automatically reduce antibiotic use,' Dr. Singhal argued. 'Better water, sanitation, hygiene, and vaccination—like typhoid vaccines—are critical long-term AMR containment tools.' A Call for National Coordination and Accountability All experts agreed that AMR cannot be tackled in silos. 'This is not just a medical or regulatory issue. It's a community issue, a veterinary issue, a poultry issue, a pharma issue. Everyone must be accountable,' Dr. Gangakhedkar stressed. Dr. Arora echoed that sentiment: 'No irrational antibiotic combinations should be manufactured or prescribed—anywhere. Regulatory agencies must crack down at the state level, and hospitals must not allow irrational drugs inside their doors.' India's AMR crisis is no longer silent—it is deafening for those willing to listen. But without systemic surveillance, public advocacy, rational prescription practices, and coordinated innovation, the country risks running out of curative options. As Dr. Gangakhedkar summed it up: 'Every patient asking, 'Do I really need this antibiotic?' is a step forward. Every death from untreatable infection must not be forgotten—it must become a rallying cry for urgent action.'
The Hindu
7 hours ago
- The Hindu
BITS Pilani Hyd scientists develop smart wound dressing to kill infection-causing bacteria
An interdisciplinary team of scientists from BITS Pilani Hyderabad campus has developed a smart wound dressing capable of killing the infection-causing bacteria and also visually signalling the presence of infection — all without the use of traditional antibiotics. The work has been published in ACS Infectious Diseases, a journal of the American Chemical Society, highlighting its promise in tackling one of the most pressing global health threats of our time—Anti-Microbial Resistance (AMR), said an official release on Monday. The study has been authored by a team comprising Vaishnavi N., Ramakrishnan Ganesan, and Jayati Ray Dutta who have also developed a user-friendly colour analysis application for instant infection assessment by analysing a photograph of the dressing. The scientists pointed out that infections at wound sites are often difficult to detect early, especially in chronic or deep wounds. Delayed diagnosis can lead to prolonged healing, the spread of infection, or even sepsis. The newly developed wound dressing addresses this issue using a multi-layered design: base layer with antibiotic-free fibres functionalised with ionic silver to kill bacteria on contact. Over this, a hydrogel layer is embedded with an enzyme-specific colour-changing compound to serve as an infection sensor. When bacteria colonise the wound, they release enzymes that migrate upward into the hydrogel layer, triggering a visible colour change — a signal that infection is present. 'Our dressing is designed to be proactive. It simultaneously kills bacteria and alerts clinicians or caregivers to the onset of infection. It does so without relying on antibiotics, which is key in the fight against drug-resistant bacteria,' said the scientists. The technology functions without the need for complex equipment or laboratory processing, making it particularly well-suited for bedside care and home use. The research team envisions the dressing being further developed into commercial point-of-care products, including infection-responsive bandages or integrated wound monitoring strips. Such products could revolutionise the way wounds are monitored and treated, especially for diabetic ulcers, post-surgical wounds, and burns. This work was supported by the Department of Science and Technology, the release added.
Business Standard
18 hours ago
- Business Standard
Wockhardt's proprietary antibiotic Zaynich gets mentioned in leading U.K. Medical Journal
For its successful use in a critically ill U.S. liver transplant patient suffering from a pan-drug resistant infection A clinically challenging case involving Wockhardt's novel antibiotic Zaynich was recently published in the July 17, 2025 issue of the Journal of Antimicrobial Chemotherapy - AMR, a leading publication by the British Society for Antimicrobial Chemotherapy. The publication details the successful use of Zaynich, a combination of Zidebactam and Cefepime, in treating a critically ill U.S. liver transplant patient suffering from a pan-drug resistant infectionan infection resistant to all available antibiotics in the United States. This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins. Notably, this patient was infected with two different pathogens - Pseudomonas and Klebsiella, both resistant to all the recently introduced antibiotics such as cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam. The case report detailed the results of genetic analysis of bacterial DNA and determined that Pseudomonas and Klebsiella harbored 4 distinct resistance mechanisms each leading to pan-drug resistance. Initially, the patient was treated for 10 weeks with cefiderocol and eravacycline (a novel tetracycline antibiotic), but the infection persisted, and the Pseudomonas strain became resistant to cefiderocol. The patient continued to suffer from fever and chills, and imaging tests showed new abscesses in the liver clear signs that the infection was not under control. Given the high risk of transplant failure due to these MDR infections, a multidisciplinary team, including microbiologists, infectious disease experts, oncologists, and transplant surgeons, sought emergency access to Zaynich. The antibiotic was administered for 14 days around the time of the liver transplant. The results were remarkable - within 11 days, the patient improved clinically and transferred from ICU to regular floor, and follow-up imaging showed no signs of active infection. Importantly, the patient remained infection-free even after six weeks of completing treatment with Zaynich, making liver transplant successful and allowing doctors to safely resume chemotherapy for the underlying cancer. The authors highlighted the role of Zaynich as a potential treatment option for extensively drug resistant infections with extremely limited/no treatment options. Zaynich is a novel, proprietary antibiotic developed by Wockhardt, combining Zidebactam and Cefepime to combat multi-drug resistant Gram-negative infections. The drug recently completed a global, pivotal Phase III clinical trial, which will support its marketing authorization across international markets. Prior to this, multiple Phase I clinical pharmacology studies involving the Zidebactam/Cefepime combination were successfully conducted in the United States. Zaynich has also completed a multi-indication clinical study in India, specifically targeting carbapenem-resistant infections. To date, more than 50 patients in India and the U.S. suffering from highly resistant infections have been treated with Zaynich under compassionate use programs.
